Science Explorer Back to mapMap
Discussion
Company · Warsaw · Poland

Celon Pharma (Poland)

celonpharma.com/enROR OpenAlex
Research works
66
▲ 39% vs 2018-21
Citations
624
9.5 per fractional work
Top-10% rate
6.3%
all institutions 10.0%
Open access
58%
world 40%
International
14%
world 18%
Celon Pharma (Poland)

Not ranked overall: Celon Pharma (Poland) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Celon Pharma (Poland) work in?

In 2022-now, 51% of research at Celon Pharma (Poland) is in Life Sciences, 30% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (35%), Medicine (30%), Immunology and Microbiology (10%). It does 2.6× the world's share of Life Sciences.

Life Sciences: 16 fractional works · 50.8% of its workBiochemistry, Genetics and Molecular Biology: 11 fractional works · 35.3% of its workMolecular Biology: 9 fractional works · 29.8% of its workCell Biology: 1 fractional works · 2.9% of its workCancer Research: 0 fractional works · 1.2% of its workBiotechnology: 0 fractional works · 1.1% of its workGenetics: 0 fractional works · 0.4% of its workImmunology and Microbiology: 3 fractional works · 9.6% of its workImmunology: 3 fractional works · 9.3% of its workMicrobiology: 0 fractional works · 0.3% of its workNeuroscience: 1 fractional works · 3.0% of its workCellular and Molecular Neuroscience: 1 fractional works · 2.5% of its workBiological Psychiatry: 0 fractional works · 0.6% of its workAgricultural and Biological Sciences: 1 fractional works · 2.1% of its workPlant Science: 0 fractional works · 1.1% of its workFood Science: 0 fractional works · 1.0% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.7% of its workPharmaceutical Science: 0 fractional works · 0.7% of its workHealth Sciences: 9 fractional works · 30.3% of its workMedicine: 9 fractional works · 30.3% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 6.5% of its workOncology: 2 fractional works · 5.7% of its workPulmonary and Respiratory Medicine: 1 fractional works · 3.7% of its workInfectious Diseases: 1 fractional works · 2.2% of its workGenetics: 1 fractional works · 1.9% of its workPhysiology: 1 fractional works · 1.9% of its workRheumatology: 0 fractional works · 1.6% of its workPharmacology: 0 fractional works · 1.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 1.3% of its workHepatology: 0 fractional works · 1.1% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.7% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.6% of its workNeurology: 0 fractional works · 0.4% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.4% of its workSurgery: 0 fractional works · 0.3% of its workEpidemiology: 0 fractional works · 0.2% of its workPhysical Sciences: 6 fractional works · 18.2% of its workChemistry: 2 fractional works · 7.7% of its workOrganic Chemistry: 1 fractional works · 4.0% of its workAnalytical Chemistry: 1 fractional works · 2.3% of its workSpectroscopy: 0 fractional works · 1.4% of its workComputer Science: 1 fractional works · 4.8% of its workComputational Theory and Mathematics: 1 fractional works · 4.8% of its workMaterials Science: 1 fractional works · 2.9% of its workMaterials Chemistry: 1 fractional works · 1.8% of its workBiomaterials: 0 fractional works · 1.1% of its workEngineering: 1 fractional works · 2.5% of its workBiomedical Engineering: 1 fractional works · 2.2% of its workElectrical and Electronic Engineering: 0 fractional works · 0.4% of its workEnvironmental Science: 0 fractional works · 0.3% of its workEnvironmental Chemistry: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 0.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.7% of its workEconomics and Econometrics: 0 fractional works · 0.7% of its workALL ITS WORKCelon Pharma(Poland)31fractional works, 2022-now
Life Sciences51%Physical Sciences18%Health Sciences30%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1135.3%
    2. Immunology and Microbiology39.6%
    3. Neuroscience13.0%
    4. Agricultural and Biological Sciences12.1%
    5. Pharmacology, Toxicology and Pharmaceutics00.7%
    1. Medicine930.3%
    1. Chemistry27.7%
    2. Computer Science14.8%
    3. Materials Science12.9%
    4. Engineering12.5%
    5. Environmental Science00.3%
    1. Economics, Econometrics and Finance00.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.44× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 6.62× its world share, 11 worksBiochemistry, Geneti…Immunology and Microbiology: 9.58× its world share, 3 worksImmunology and Micro…Neuroscience: 1.86× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.16× its world share, 0 worksPharmacology, Toxico…Chemistry: 4.90× its world share, 2 worksChemistryComputer Science: 0.62× its world share, 2 worksComputer ScienceEngineering: 0.17× its world share, 1 worksEngineeringEnvironmental Science: 0.05× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.84× its world share, 1 worksMaterials ScienceMedicine: 1.57× its world share, 9 worksMedicineEconomics, Econometrics and Finance: 0.34× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.6×. Every wedge is a field page.

All 12 fields, with their numbers
  1. Immunology and Microbiology9.58×3 works
  2. Biochemistry, Genetics and Molecular Biology6.62×11 works
  3. Chemistry4.90×2 works
  4. Pharmacology, Toxicology and Pharmaceutics2.16×0 works
  5. Neuroscience1.86×1 works
  6. Medicine1.57×9 works
  7. Materials Science0.84×1 works
  8. Computer Science0.62×2 works
  9. Agricultural and Biological Sciences0.44×1 works
  10. Economics, Econometrics and Finance0.34×0 works
  11. Engineering0.17×1 works
  12. Environmental Science0.05×0 works

Who are the top researchers at Celon Pharma (Poland)?

Ranked on the quality score, Daria Zdżalik-Bielecka, Filip Mituła and Aleksandra M. Stanczak lead among researchers whose main affiliation is Celon Pharma (Poland).

  1. 1 Daria Zdżalik-Bielecka Poland · #1,212,950 worldwide 737 citations · 30 works
  2. 2 Filip Mituła Poland · #2,401,408 worldwide 334 citations · 21 works
  3. 3 Aleksandra M. Stanczak Poland · #3,276,023 worldwide 419 citations · 40 works
  4. 4 Monika Lamparska‐Przybysz Poland · #3,498,275 worldwide 553 citations · 35 works
  5. 5 Paweł Gunerka Poland · #3,733,627 worldwide 171 citations · 20 works
  6. 6 Joanna Hucz‐Kalitowska Poland · #3,803,388 worldwide 102 citations · 15 works
  7. 7 Delfina Popiel Poland · #4,193,696 worldwide 693 citations · 43 works
  8. 8 Damian A. Smuga Poland · #4,340,939 worldwide 307 citations · 26 works
  9. 9 Monika Skupińska Poland · #4,451,668 worldwide 76 citations · 19 works
  10. 10 Sylwia Janowska Poland · #4,516,775 worldwide 173 citations · 32 works
All ranked researchers at Celon Pharma (Poland)

What are the most cited papers from Celon Pharma (Poland)?

The most cited paper from Celon Pharma (Poland) is "Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial" (Jonathan M. Spergel, Marc E. Rothenberg, Margaret H. Collins et al., 2011), with 556 citations. Next come "Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer" (81) and "Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma" (78).

Most cited papers
#PaperReleasedCitations
1 Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial Jonathan M. Spergel, Marc E. Rothenberg, Margaret H. Collins et al. · Journal of Allergy and Clinical Immunology 30 Dec 2011 556
2 Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer Lubomir Bodnar, Aleksandra M. Stanczak, Szczepan Cierniak et al. · Journal of Ovarian Research Open access 2014 81
3 Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma Aleksandra M. Stanczak, Rafał Stec, Lubomir Bodnar et al. · Pathology & Oncology Research Open access 15 Jun 2011 78
4 Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells Paulina Grygielewicz, Barbara Dymek, Anna Bujak et al. · Gastric Cancer Open access 19 Nov 2014 72
5 Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Damian A. Smuga et al. · Biomedicines Open access 11 Oct 2023 63
All 60 most cited papers, with filters and sorting

Which keywords describe research at Celon Pharma (Poland)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Cancer, Macrophages, Glycosylation, Immune Regulation, Monoclonal Antibodies, apoptotic cells, CD47 and Metabolism.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 28 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 28 words, with their numbers
  1. Cancer4▲ 8.7×7 topics
  2. Macrophages3▲ 47×2 topics
  3. Glycosylation2▲ 74×2 topics
  4. Immune Regulation2▲ 69×2 topics
  5. Monoclonal Antibodies2▲ 87×3 topics
  6. CD472▲ 393×1 topic
  7. apoptotic cells2▲ 393×1 topic
  8. Metabolism2▲ 14×2 topics
  9. Signaling2▲ 124×2 topics
  10. Therapeutic Antibodies2▲ 101×2 topics
  11. Medicinal Chemistry2▲ 25×4 topics
  12. Obesity2▲ 8.7×3 topics
  13. Antibody Engineering2▲ 119×1 topic
  14. Development2▲ 18×2 topics
  15. Fc Receptors2▲ 119×1 topic
  16. FGF212▲ 503×1 topic
  17. Fibroblast Growth Factor2▲ 503×1 topic
  18. Inflammation2▲ 2.7×8 topics
  19. Machine Learning2▲ 1.63×2 topics
  20. Cancer Therapy2▲ 9.0×7 topics
  21. Tumor Microenvironment2▲ 12×4 topics
  22. Molecular Docking2▲ 39×1 topic
  23. Virtual Screening2▲ 53×1 topic
  24. Drug Discovery1▲ 20×3 topics
  25. Oxidative Stress1▲ 2.8×7 topics
  26. Therapeutic Targets1▲ 30×4 topics
  27. Transcriptional Regulation1▲ 26×2 topics
  28. Biomedical Applications1▲ 2.8×2 topics

Which research topics does Celon Pharma (Poland) publish most on?

By volume in 2022-now: Phagocytosis and Immune Regulation, Monoclonal and Polyclonal Antibodies Research, Fibroblast Growth Factor Research and Computational Drug Discovery Methods.

Phagocytosis and Immune Regulation: 2 fractional worksMonoclonal and Polyclonal Antibodies Research: 2 fractional worksFibroblast Growth Factor Research: 2 fractional worksComputational Drug Disco…2Computational Drug Discovery Methods: 2 fractional worksProtein Degradation and Inhibitors: 1 fractional worksInnovative Microfluidic and Catalytic Techniques Innovation: 1 fractional worksPhosphodiesterase function and regulation: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksReceptor Mechanisms and Signaling: 1 fractional worksMetabolomics and Mass Spectrometry Studies: 1 fractional works
ImmunologyRadiology, Nuclear Medicine and ImagingMolecular BiologyComputational Theory and Mathematics2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Phagocytosis and Immune Regulation Immunology 2 works
  2. 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
  3. 3 Fibroblast Growth Factor Research Molecular Biology 2 works
  4. 4 Computational Drug Discovery Methods Computational Theory and Mathematics 2 works
  5. 5 Protein Degradation and Inhibitors Molecular Biology 1 works
  6. 6 Innovative Microfluidic and Catalytic Techniques Innovation Biomedical Engineering 1 works
  7. 7 Phosphodiesterase function and regulation Molecular Biology 1 works
  8. 8 Cancer Immunotherapy and Biomarkers Oncology 1 works
  9. 9 Receptor Mechanisms and Signaling Molecular Biology 1 works
  10. 10 Metabolomics and Mass Spectrometry Studies Molecular Biology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available57.5%not open42.5%

World: 40% of research is openly available.

with international co-authors13.9%domestic only86.1%

World: 18% is written across borders.

How has Celon Pharma (Poland)'s research output changed?

Output in 2022-2025 was 39% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Celon Pharma (Poland) as a percentage of every work published that year, 0.00015% in 2024.

still counting0.00010%0.00020%Celon Pharma (Poland)0.000072% in 202520102020

Fractional works of Celon Pharma (Poland) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Warsaw

All research institutions in Warsaw

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Celon Pharma (Poland). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.